Vaccine Miracles: Does JNJ Kill the Profit Path for MRNA and NVAX?

Investor Tips
New vaccine entrant gets approval before Novavax, while herd immunity ideas put sales in doubt.

Articles You May Like

Stocks making the biggest moves before the bell: Alibaba, Lyft, Walgreens and more
Deutsche Bank shares slide after sudden spike in the cost of insuring against its default
Social Security trust funds depletion date moves one year earlier to 2034, Treasury says
Why you may be subsidizing a coworker’s 401(k) fees
Mortgage demand gets a boost from bank volatility, but it may be short-lived